UA79610C2 - Solid dispersion composition - Google Patents

Solid dispersion composition Download PDF

Info

Publication number: UA79610C2
Authority: UA; Ukraine
Prior art keywords: compound; solid dispersion; glycol; polyoxyethylene; dispersion composition
Prior art date: 2002-04-16

Application number

UA20041109330A

Other languages

English (en)

Ukrainian (uk)

Inventor

Niichiro Takano

Hiroyuki Kawashima

Yasuo Shinoda

Toshio Inagi

Original Assignee

Kowa Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-16

Filing date

2003-04-15

Publication date

2007-07-10

2003-04-15 Application filed by Kowa Co filed Critical Kowa Co

2007-07-10 Publication of UA79610C2 publication Critical patent/UA79610C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 42
239000007962 solid dispersion Substances 0.000 title claims abstract description 13
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 54
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 27
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 20
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 19
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 19
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 19
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract description 14
239000007787 solid Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 10
238000012876 topography Methods 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
150000001875 compounds Chemical class 0.000 abstract description 5
HEUAVAATAFEENP-UHFFFAOYSA-N 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CC=C1 HEUAVAATAFEENP-UHFFFAOYSA-N 0.000 abstract 2
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
229940125904 compound 1 Drugs 0.000 description 30
-1 hydroxypropoxy groups Chemical group 0.000 description 25
229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
238000000034 method Methods 0.000 description 13
229920001451 polypropylene glycol Polymers 0.000 description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
230000000052 comparative effect Effects 0.000 description 10
239000002245 particle Substances 0.000 description 8
239000008187 granular material Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000003814 drug Substances 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000007922 dissolution test Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
229950008138 carmellose Drugs 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000000790 scattering method Methods 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
108010011485 Aspartame Proteins 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010016818 Fluorosis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003810 Interleukin-18 Human genes 0.000 description 1
108090000171 Interleukin-18 Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
244000228451 Stevia rebaudiana Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
239000007771 core particle Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
208000004042 dental fluorosis Diseases 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000012812 general test Methods 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 1
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229940078492 ppg-17 Drugs 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)

UA20041109330A 2002-04-16 2003-04-15 Solid dispersion composition UA79610C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37241602P	2002-04-16	2002-04-16
PCT/JP2003/004762 WO2003086405A1 (en)	2002-04-16	2003-04-15	Solid dispersion composition

Publications (1)

Publication Number	Publication Date
UA79610C2 true UA79610C2 (en)	2007-07-10

Family

ID=29250849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041109330A UA79610C2 (en)	2002-04-16	2003-04-15	Solid dispersion composition

Country Status (21)

Country	Link
US (1)	US6753330B2 (is)
EP (1)	EP1495759A4 (is)
JP (1)	JP4295629B2 (is)
KR (1)	KR20040101437A (is)
CN (1)	CN1291719C (is)
AU (1)	AU2003235156B2 (is)
BR (1)	BR0309212A (is)
CA (1)	CA2481595A1 (is)
EA (1)	EA007153B1 (is)
HR (1)	HRP20040959A2 (is)
IL (2)	IL164206A0 (is)
IS (1)	IS7488A (is)
MX (1)	MXPA04010174A (is)
MY (1)	MY128945A (is)
NO (1)	NO20044337L (is)
NZ (1)	NZ535541A (is)
PL (1)	PL372980A1 (is)
TW (1)	TWI319772B (is)
UA (1)	UA79610C2 (is)
WO (1)	WO2003086405A1 (is)
ZA (1)	ZA200407657B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004096281A1 (ja) *	2003-04-29	2004-11-11	Kowa Co., Ltd.	溶出性に優れた超難水溶性薬物含有組成物及びその製造法
EP1650195A4 (en) *	2003-07-30	2008-09-17	Kowa Co	METHOD FOR INHIBITING OSTEOPONTIN PRODUCTION
WO2005034999A2 (en) *	2003-10-10	2005-04-21	Bvm Holding Co.	Composition comprising association complex of a pharmaceutical and a poloxamer
JP2006001859A (ja) *	2004-06-16	2006-01-05	Shiseido Co Ltd	絆創膏組成物
WO2006080312A1 (ja) *	2005-01-25	2006-08-03	Kowa Co., Ltd.	吸着多孔体の製造法
KR20080038339A (ko) *	2005-08-31	2008-05-06	코와 가부시키가이샤	관절 류머티즘의 예방 및/또는 치료법
WO2008064259A2 (en) *	2006-11-21	2008-05-29	Biokey, Inc.	Solid dispersion composition comprising fluvastatin
JP2009155282A (ja) *	2007-12-27	2009-07-16	Kowa Co	固体分散体含有医薬組成物
DE102008047910A1 (de) *	2008-09-19	2010-03-25	Molkerei Meggle Wasserburg Gmbh & Co. Kg	Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2019241077A1 (en)	2018-06-11	2019-12-19	Abon Pharmaceuticals Llc.	Oral eliglustat transmucosal delivery system
JP7377782B2 (ja) *	2019-09-04	2023-11-10	信越化学工業株式会社	フィルム成形用組成物及びフィルム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4314196A (en) *	1994-12-21	1996-07-10	Yamanouchi Pharmaceutical Co., Ltd.	Solid composition with improved solubility and absorbability
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
CN1142148C (zh) *	1997-11-19	2004-03-17	兴和株式会社	新颖的哒嗪衍生物和含有其作为有效成分的药物
JP3335132B2 (ja) *	1997-11-19	2002-10-15	興和株式会社	新規ピリダジン誘導体及びこれを有効成分とする医薬
BR0014469A (pt) *	1999-10-04	2002-06-11	Asahi Chemical Ind	Processo para melhorar a solubilidade de um derivado de amino álcool tricìclico, composição farmacêutica, processo para preparar a mesma, e, derivado de amino álcool tricìclico
JP2004131393A (ja) *	2002-10-08	2004-04-30	Kowa Co	易溶出性製剤

2003
- 2003-04-09 MY MYPI20031301A patent/MY128945A/en unknown
- 2003-04-15 EP EP03746488A patent/EP1495759A4/en not_active Withdrawn
- 2003-04-15 MX MXPA04010174A patent/MXPA04010174A/es active IP Right Grant
- 2003-04-15 NZ NZ535541A patent/NZ535541A/en unknown
- 2003-04-15 UA UA20041109330A patent/UA79610C2/uk unknown
- 2003-04-15 WO PCT/JP2003/004762 patent/WO2003086405A1/ja not_active Ceased
- 2003-04-15 CN CNB038083795A patent/CN1291719C/zh not_active Expired - Fee Related
- 2003-04-15 IL IL16420603A patent/IL164206A0/xx active IP Right Grant
- 2003-04-15 PL PL03372980A patent/PL372980A1/xx not_active Application Discontinuation
- 2003-04-15 BR BR0309212-7A patent/BR0309212A/pt not_active IP Right Cessation
- 2003-04-15 JP JP2003583424A patent/JP4295629B2/ja not_active Expired - Fee Related
- 2003-04-15 HR HRP20040959 patent/HRP20040959A2/hr not_active Application Discontinuation
- 2003-04-15 CA CA002481595A patent/CA2481595A1/en not_active Abandoned
- 2003-04-15 EA EA200401377A patent/EA007153B1/ru not_active IP Right Cessation
- 2003-04-15 KR KR10-2004-7016203A patent/KR20040101437A/ko not_active Abandoned
- 2003-04-15 AU AU2003235156A patent/AU2003235156B2/en not_active Ceased
- 2003-04-16 TW TW092108801A patent/TWI319772B/zh not_active IP Right Cessation
- 2003-04-16 US US10/414,008 patent/US6753330B2/en not_active Expired - Fee Related
2004
- 2004-09-21 IL IL164206A patent/IL164206A/en not_active IP Right Cessation
- 2004-09-22 ZA ZA200407657A patent/ZA200407657B/en unknown
- 2004-10-04 IS IS7488A patent/IS7488A/is unknown
- 2004-10-12 NO NO20044337A patent/NO20044337L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1291719C (zh)	2006-12-27
AU2003235156B2 (en)	2007-07-05
PL372980A1 (en)	2005-08-08
HRP20040959A2 (en)	2004-12-31
TWI319772B (en)	2010-01-21
EP1495759A4 (en)	2010-12-29
BR0309212A (pt)	2005-02-09
EA200401377A1 (ru)	2005-06-30
JP4295629B2 (ja)	2009-07-15
IL164206A0 (en)	2005-12-18
AU2003235156A1 (en)	2003-10-27
TW200408671A (en)	2004-06-01
CA2481595A1 (en)	2003-10-23
MY128945A (en)	2007-03-30
HK1082669A1 (en)	2006-06-16
JPWO2003086405A1 (ja)	2005-08-18
CN1646128A (zh)	2005-07-27
AU2003235156B9 (en)	2003-10-27
EA007153B1 (ru)	2006-08-25
US20040019122A1 (en)	2004-01-29
US6753330B2 (en)	2004-06-22
NO20044337L (no)	2004-10-12
WO2003086405A1 (en)	2003-10-23
EP1495759A1 (en)	2005-01-12
IS7488A (is)	2004-10-04
NZ535541A (en)	2006-09-29
MXPA04010174A (es)	2005-02-03
KR20040101437A (ko)	2004-12-02
ZA200407657B (en)	2006-07-26
IL164206A (en)	2008-04-13

Publication	Publication Date	Title
KR102265644B1 (ko)	2021-06-16	글루코키나아제 활성화제의 경구제제 및 이의 제조방법
TWI673051B (zh)	2019-10-01	恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
JP5054061B2 (ja)	2012-10-24	ピリミジン−スルファミドを含む安定な医薬組成物
KR100348842B1 (ko)	2002-12-31	염기성물질로안정화된약제학적조성물
JP2010047612A (ja)	2010-03-04	ナテグリニド含有製剤
UA79610C2 (en)	2007-07-10	Solid dispersion composition
JPWO2007097325A1 (ja)	2009-07-16	リン酸オセルタミビル含有医薬組成物
JP2004131393A (ja)	2004-04-30	易溶出性製剤
BG63528B1 (bg)	2002-04-30	Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик
WO2013114389A1 (en)	2013-08-08	Process for preparing solid oral formulations comprising low dose of entecavir
JP4572300B2 (ja)	2010-11-04	ピモベンダン経口投与製剤
JP5103173B2 (ja)	2012-12-19	ジヒドロピリジン系化合物の分解を防止する方法
JP2005060310A (ja)	2005-03-10	不快な味をマスキングする経口投与用製剤
WO2019221215A1 (ja)	2019-11-21	ルビプロストン含有粒子状医薬組成物
CA3046861C (en)	2025-12-02	Oral preparation of glucokinase activator and preparation method therefor
JP2019073488A (ja)	2019-05-16	アプレピタントを有効成分とする医薬錠剤
JPH04230626A (ja)	1992-08-19	改良されたゲムフィブロジル組成物
JP2002087959A (ja)	2002-03-27	易吸収性ニルバジピン錠の製造法
EP4456983A1 (en)	2024-11-06	Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients
JP2003321397A (ja)	2003-11-11	易溶出性製剤
JP2004067533A (ja)	2004-03-04	易溶出性製剤
WO2018079734A1 (ja)	2018-05-03	メマンチンまたはその薬学上許容される塩を含有する医薬組成物
BRPI0607372B1 (pt)	2019-04-30	Medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo
WO2012060789A2 (en)	2012-05-10	Production method for cefdinir formulations
PT1438961E (pt)	2007-05-31	Composição bioquivalente de itraconazol disperso num polímero hidrofílico.